Why Attend?
Now in its 6th year, the Dermatology Drug Development Summit Europe continues to be the go-to meeting for biopharma leaders shaping the future of immunodermatology. As modalities diversify, targeted indications expand, and inflammatory pathways are increasingly elucidated, the need to differentiate your pipelines in an evolving landscape has never been greater.
Here are some highlights from this year's agenda:
- Gain cutting-edge disease biology insights with a presentation from Noa Therapeutics’ CSO, Serene Mandla: "Biological Crossovers: Uncovering Disease Targets with Biological Relevance Across Multiple Diseases."
- Hear diverse perspectives on the challenges of designing trials for Hidradenitis Suppurativa, considering varied endpoint requirements across different regulatory environments. The panel features C-level representatives from biotechs including Moonlake Immunotherapeutics, InflaRx, and CiryTll Therapeutics.
- Explore new immuno-dermatology modalities, including a presentation on gene-silencing siRNA biologics from Lars French, CMO of Alys Pharmaceuticals.
Find full session descriptions in the agenda here:
What Will You Gain?
Who Will You Meet?
This summit is designed for senior leaders in R&D, Clinical Development, Medical Affairs, and Regulatory Affairs from biotech and pharma companies advancing immunodermatology pipelines. Whether you're refining clinical strategies, exploring novel targets, or overcoming development bottlenecks, this event delivers the critical insights and networking opportunities needed to drive your dermatology programs forward.
What Your Peers Have to Say
“Excellent networking with colleges who are really dedicated to dermatology drug development.” - Eurofins
“I enjoyed attending and speaking at Hanson Wade summit. It is a great way to network. I enjoy the round table discussions and exposure to various facets of drug discovery.” - Merck & Co
“The intimate and transparent atmosphere, the dedicated networking sessions, the relevance & quality of the presentations and the number of dermatology leaders attending were all great.” - Sanos Group

"The format really favours networking, the congress has a reasonable size enabling discussion with everyone" - Nuvisan Pharma Services Group